Nila Hemed

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

Gadi Lalazar, Meir Mizrahi, Ilit Turgeman et al. · Journal of Clinical Immunology · 2015 · 75 citations

Life Sciences, Endocrinology, Immunology +17

Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells

Yaron Ilan, Ehud Zigmond, Gadi Lalazar et al. · Journal of Clinical Immunology · 2009 · 67 citations · Full text

Life Sciences, Immunology, Pharmacokinetics +10

Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial

Tal Sigawi, Ram Gelman, Ofra Maimon et al. · Frontiers in Oncology · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacology +13